Literature DB >> 2941292

Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

J Guibert, D Destrée, C Konopka, J Acar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941292     DOI： 10.1007/bf02014000

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  10 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  [Clinical evaluation of cefmenoxime in urinary tract and prostatic infections].

Authors:  J Guibert; J F Acar; D Destree; A Bryskier
Journal:  Pathol Biol (Paris)       Date:  1985-05

3.  [Clinical evaluation of azthreonam in severe urinary tract infections].

Authors:  J Guibert; J F Acar; M Miegi
Journal:  Pathol Biol (Paris)       Date:  1984-05

4.  [Clinical evaluation of cefotaxime at various dosage levels in urinary tract infections (author's transl)].

Authors:  J Guibert; J F Acar; C Justin; M D Kitzis
Journal:  Nouv Presse Med       Date:  1981-02-26

5.  [Clinical evaluation of cefotiam in adults urinary tract infections (author's transl)].

Authors:  J Guibert; H Coppens; C Yvelin
Journal:  Pathol Biol (Paris)       Date:  1982-06

6.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

10.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191
  10 in total
  10 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

Authors:  V Prát; M Horcicková; K Matousovic; M Hatala
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 3.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 4.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

Review 5.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

6.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

Authors:  T J Louie
Journal:  CMAJ       Date:  1994-03-01       Impact factor: 8.262

Review 8.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Use of quinolones in treatment of prostatitis and lower urinary tract infections.

Authors:  V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.